文献速递腹部介入CTMR

LI-RADS放射治疗反应评估v2024与改良RECIST的对比评估

Evaluation of the LI-RADS radiation treatment response assessment v2024 in comparison with the modified RECIST.
PubMed 文献 · Eur Radiol · 2025-06-05

本研究为单中心回顾性研究,纳入2011至2023年间接受经动脉放射栓塞或外照射放疗的115例肝细胞癌患者,由两名腹部放射科医师独立评估治疗后3个月的首次影像学反应,比较mRECIST、LR-TRA v2017与放射LR-TRA v2024,并分析反应类别与总生存期的关联。

要点

  • 放射LR-TRA v2024中可存活、无进展、不可存活率分别为47%、51.3%、1.7%。
  • 随访期间LR-TR无进展比例下降,而LR-TR不可存活比例随时间增加。
  • 随访中达到不可存活疾病与总生存期改善强烈相关(p < 0.001)。

核心结论

  • 放射LR-TRA v2024有效反映了放射治疗后典型的延迟反应模式,便于临床管理和沟通。

研究设计与样本

  • 单中心回顾性研究,纳入2011至2023年间连续接受经动脉放射栓塞或外照射放疗的肝细胞癌患者115例,由两名腹部放射科医师独立评估治疗后3个月的首次影像学反应。

诊断标准与关键数值

  • mRECIST评估:完全缓解36.5%(44/115)、部分缓解26.1%(30/115)、疾病稳定17.4%(20/115)、疾病进展20%(26/115)。
  • LR-TRA v2017评估:不可存活48.7%(56/115)、不确定13%(15/115)、可存活38.3%(44/115)。
  • 放射LR-TRA v2024评估:不可存活47%(54/115)、无进展51.3%(59/115)、可存活1.7%(2/115)。

临床应用与阅片要点

  • 放射LR-TRA v2024通过纳入时间变化概念和LR-TR无进展疾病,可支持观察等待方案。
  • 随访中达到不可存活疾病与总生存期改善强烈相关(p < 0.001)。
  • 随访期间LR-TR无进展比例下降,而LR-TR不可存活比例随时间增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Conventional radiologic response criteria inadequately address imaging features and delayed responses after radiation-based therapies, limiting clinical decisions. This study evaluated treatment response to radiation-based locoregional therapies using modified RECIST (mRECIST), LI-RADS treatment response algorithm (LR-TRA) v2017, and radiation LR-TRA v2024, assessed changes in response categories during follow-up, and evaluated their association with overall survival (OS).

MATERIALS AND METHODS: This single-center retrospective study included consecutive patients with hepatocellular carcinoma treated with transarterial radioembolization or external beam radiation therapy between 2011 and 2023. Two abdominal radiologists independently assessed the first radiologic response 3 months post-treatment using the mRECIST, LR-TRA v2017, and radiation LR-TRA v2024. The changes in the mRECIST and LR-TR categories during follow-up were evaluated. The Cox proportional hazard model was used to assess the association between response categories and OS.

RESULTS: A total of 115 patients were included (66.6 ± 12.9 years; 73.9% [85/115] men). Complete response (CR), partial response, stable disease, and progressive disease (PD) based on the mRECIST were 36.5% (44/115), 26.1% (30/115), 17.4% (20/115), and 20% (26/115), respectively. In LR-TRA v2017, the nonviable, equivocal, and viable rates were 48.7% (56/115), 13% (15/115), and 38.3% (44/115), respectively. In LR-TRA v2024, the nonviable, nonprogressing, and viable rates were 47% (54/115), 51.3% (59/115), and 1.7% (2/115), respectively. During follow-up, the proportion of LR-TR nonprogressing decreased, while that of LR-TR nonviable increased over time. Achieving nonviable disease during follow-up was strongly associated with improved OS (p < 0.001).

CONCLUSION: Radiation LR-TRA v2024 effectively reflected a typical delayed response pattern after radiation-based therapy.

KEY POINTS: Question Conventional radiologic response criteria do not fully address the imaging features and delayed response pattern after radiation-based therapies, limiting clinical decision making. Findings The new LI-RADS radiation treatment response assessment v2024 (LR-TRA v2024) effectively reflects unique post-treatment imaging features and delayed response to radiation-based treatment, facilitating management and communication. Clinical relevance The new radiation LR-TRA v2024 captured the evolving nature of post-radiation imaging features by incorporating the concept of temporal change and LR-TR nonprogressing disease to allow for a watch-and-wait protocol.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Kim H, Kim B, Son SH, et al. Evaluation of the LI-RADS radiation treatment response assessment v2024 in comparison with the modified RECIST. Eur Radiol. 2025. PMID: 40471267. doi:10.1007/s00330-025-11730-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。